PolyPeptide Group AG (LON:0AAJ)

Market Cap	1.21B +66.4%
Revenue (ttm)	395.11M +24.4%
Net Income	12.44M
EPS	0.37
Shares Out	n/a
PE Ratio	98.92
Forward PE	42.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	40.45
Previous Close	40.50
Day's Range	40.45 - 40.45
52-Week Range	21.95 - 50.00
Beta	1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 9, 2027

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,460
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0AAJ

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error